Global Recombinant Proteins

Recombinant Proteins Comprehensive Study by Type (Cytokines & Growth Factors {Interferons (IFNs), Interleukins (ILs), Others}, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes {Kinases, Metabolic enzymes, Others}, Recombinant Regulatory Protein, Hormones, Other), Application (Drug Discovery & Development, Therapeutics {Biologics, Vaccines, Cell & Gene Therapies, Others}, Research, Others), End Use (Biopharmaceutical Companies, Academic and Research Institutes, Contract Research Organizations, Diagnostic Laboratories, Others) Players and Region - Global Market Outlook to 2032

Recombinant Proteins Market by XX Submarkets | Forecast Years 2025-2032  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Recombinant Proteins
Unnatural proteins are proteins that have been produced by genes that are coded by recombinant DNA, where the gene of the target protein is placed behind a promoter sequence in a plasmid. Once the construct is placed into a host system, the host's protein synthesis capabilities produce the desired protein, which is then available in high amounts for application in research, diagnosis or treatment. In producing recombinant proteins, the first step is to create the recombinant DNA using either molecular cloning or PCR. Molecular cloning is a process of removing DNA from a cell and putting it into a plasmid which is then copied in a cell such as E. coli. Samba is a different approach where the PCR is used in vitro to amplify a DNA sequence from a template without the need for vectors or hosts.

AttributesDetails
Study Period2020-2032
Base Year2024
UnitValue (USD Million)


Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Sino Biological, Inc. (China), Bio-Techne (USA), GenScript (USA), Bio-Rad Laboratories, Inc. (USA), Merck KGaA (Germany), Thermo Fisher Scientific (USA), Proteintech Group, Inc. (USA), Enzo Life Sciences, Inc. (USA), Abnova Corporation (Taiwan), RayBiotech Life Inc. (USA) and STEMCELL Technologies Inc. (Canada) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Recombinant Proteins market by Type (Cytokines & Growth Factors {Interferons (IFNs), Interleukins (ILs), Others}, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes {Kinases, Metabolic enzymes, Others}, Recombinant Regulatory Protein, Hormones and Other), Application (Drug Discovery & Development, Therapeutics {Biologics, Vaccines, Cell & Gene Therapies, Others}, Research and Others) and Region.



On the basis of geography, the market of Recombinant Proteins has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End Use, the sub-segment i.e. Biopharmaceutical Companies will boost the Recombinant Proteins market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.



About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Cytokines & Growth Factors {Interferons (IFNs), Interleukins (ILs), Others}
  • Antibodies
  • Immune checkpoint proteins
  • Virus Antigens
  • Enzymes {Kinases, Metabolic enzymes, Others}
  • Recombinant Regulatory Protein
  • Hormones
  • Other
By Application
  • Drug Discovery & Development
  • Therapeutics {Biologics, Vaccines, Cell & Gene Therapies, Others}
  • Research
  • Others
By End Use
  • Biopharmaceutical Companies
  • Academic and Research Institutes
  • Contract Research Organizations
  • Diagnostic Laboratories
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Factor Analysis
    • 3.1. Porters Five Forces
    • 3.2. Supply/Value Chain
    • 3.3. PESTEL analysis
    • 3.4. Market Entropy
    • 3.5. Patent/Trademark Analysis
  • 4. Global Recombinant Proteins, by Type, Application, End Use and Region (value) (2019-2024)
    • 4.1. Introduction
    • 4.2. Global Recombinant Proteins (Value)
      • 4.2.1. Global Recombinant Proteins by: Type (Value)
        • 4.2.1.1. Cytokines & Growth Factors {Interferons (IFNs), Interleukins (ILs), Others}
        • 4.2.1.2. Antibodies
        • 4.2.1.3. Immune checkpoint proteins
        • 4.2.1.4. Virus Antigens
        • 4.2.1.5. Enzymes {Kinases, Metabolic enzymes, Others}
        • 4.2.1.6. Recombinant Regulatory Protein
        • 4.2.1.7. Hormones
        • 4.2.1.8. Other
      • 4.2.2. Global Recombinant Proteins by: Application (Value)
        • 4.2.2.1. Drug Discovery & Development
        • 4.2.2.2. Therapeutics {Biologics, Vaccines, Cell & Gene Therapies, Others}
        • 4.2.2.3. Research
        • 4.2.2.4. Others
      • 4.2.3. Global Recombinant Proteins by: End Use (Value)
        • 4.2.3.1. Biopharmaceutical Companies
        • 4.2.3.2. Academic and Research Institutes
        • 4.2.3.3. Contract Research Organizations
        • 4.2.3.4. Diagnostic Laboratories
        • 4.2.3.5. Others
      • 4.2.4. Global Recombinant Proteins Region
        • 4.2.4.1. South America
          • 4.2.4.1.1. Brazil
          • 4.2.4.1.2. Argentina
          • 4.2.4.1.3. Rest of South America
        • 4.2.4.2. Asia Pacific
          • 4.2.4.2.1. China
          • 4.2.4.2.2. Japan
          • 4.2.4.2.3. India
          • 4.2.4.2.4. South Korea
          • 4.2.4.2.5. Taiwan
          • 4.2.4.2.6. Australia
          • 4.2.4.2.7. Rest of Asia-Pacific
        • 4.2.4.3. Europe
          • 4.2.4.3.1. Germany
          • 4.2.4.3.2. France
          • 4.2.4.3.3. Italy
          • 4.2.4.3.4. United Kingdom
          • 4.2.4.3.5. Netherlands
          • 4.2.4.3.6. Rest of Europe
        • 4.2.4.4. MEA
          • 4.2.4.4.1. Middle East
          • 4.2.4.4.2. Africa
        • 4.2.4.5. North America
          • 4.2.4.5.1. United States
          • 4.2.4.5.2. Canada
          • 4.2.4.5.3. Mexico
  • 5. Recombinant Proteins: Manufacturers/Players Analysis
    • 5.1. Competitive Landscape
      • 5.1.1. Market Share Analysis
        • 5.1.1.1. Top 3
        • 5.1.1.2. Top 5
    • 5.2. Peer Group Analysis (2024)
    • 5.3. BCG Matrix
    • 5.4. Company Profile
      • 5.4.1. Sino Biological, Inc. (China)
        • 5.4.1.1. Business Overview
        • 5.4.1.2. Products/Services Offerings
        • 5.4.1.3. Financial Analysis
        • 5.4.1.4. SWOT Analysis
      • 5.4.2. Bio-Techne (USA)
        • 5.4.2.1. Business Overview
        • 5.4.2.2. Products/Services Offerings
        • 5.4.2.3. Financial Analysis
        • 5.4.2.4. SWOT Analysis
      • 5.4.3. GenScript (USA)
        • 5.4.3.1. Business Overview
        • 5.4.3.2. Products/Services Offerings
        • 5.4.3.3. Financial Analysis
        • 5.4.3.4. SWOT Analysis
      • 5.4.4. Bio-Rad Laboratories, Inc. (USA)
        • 5.4.4.1. Business Overview
        • 5.4.4.2. Products/Services Offerings
        • 5.4.4.3. Financial Analysis
        • 5.4.4.4. SWOT Analysis
      • 5.4.5. Merck KGaA (Germany)
        • 5.4.5.1. Business Overview
        • 5.4.5.2. Products/Services Offerings
        • 5.4.5.3. Financial Analysis
        • 5.4.5.4. SWOT Analysis
      • 5.4.6. Thermo Fisher Scientific (USA)
        • 5.4.6.1. Business Overview
        • 5.4.6.2. Products/Services Offerings
        • 5.4.6.3. Financial Analysis
        • 5.4.6.4. SWOT Analysis
      • 5.4.7. Proteintech Group, Inc. (USA)
        • 5.4.7.1. Business Overview
        • 5.4.7.2. Products/Services Offerings
        • 5.4.7.3. Financial Analysis
        • 5.4.7.4. SWOT Analysis
      • 5.4.8. Enzo Life Sciences, Inc. (USA)
        • 5.4.8.1. Business Overview
        • 5.4.8.2. Products/Services Offerings
        • 5.4.8.3. Financial Analysis
        • 5.4.8.4. SWOT Analysis
      • 5.4.9. Abnova Corporation (Taiwan)
        • 5.4.9.1. Business Overview
        • 5.4.9.2. Products/Services Offerings
        • 5.4.9.3. Financial Analysis
        • 5.4.9.4. SWOT Analysis
      • 5.4.10. RayBiotech Life Inc. (USA)
        • 5.4.10.1. Business Overview
        • 5.4.10.2. Products/Services Offerings
        • 5.4.10.3. Financial Analysis
        • 5.4.10.4. SWOT Analysis
      • 5.4.11. STEMCELL Technologies Inc. (Canada)
        • 5.4.11.1. Business Overview
        • 5.4.11.2. Products/Services Offerings
        • 5.4.11.3. Financial Analysis
        • 5.4.11.4. SWOT Analysis
  • 6. Global Recombinant Proteins Sale, by Type, Application, End Use and Region (value) (2027-2032)
    • 6.1. Introduction
    • 6.2. Global Recombinant Proteins (Value)
      • 6.2.1. Global Recombinant Proteins by: Type (Value)
        • 6.2.1.1. Cytokines & Growth Factors {Interferons (IFNs), Interleukins (ILs), Others}
        • 6.2.1.2. Antibodies
        • 6.2.1.3. Immune checkpoint proteins
        • 6.2.1.4. Virus Antigens
        • 6.2.1.5. Enzymes {Kinases, Metabolic enzymes, Others}
        • 6.2.1.6. Recombinant Regulatory Protein
        • 6.2.1.7. Hormones
        • 6.2.1.8. Other
      • 6.2.2. Global Recombinant Proteins by: Application (Value)
        • 6.2.2.1. Drug Discovery & Development
        • 6.2.2.2. Therapeutics {Biologics, Vaccines, Cell & Gene Therapies, Others}
        • 6.2.2.3. Research
        • 6.2.2.4. Others
      • 6.2.3. Global Recombinant Proteins by: End Use (Value)
        • 6.2.3.1. Biopharmaceutical Companies
        • 6.2.3.2. Academic and Research Institutes
        • 6.2.3.3. Contract Research Organizations
        • 6.2.3.4. Diagnostic Laboratories
        • 6.2.3.5. Others
      • 6.2.4. Global Recombinant Proteins Region
        • 6.2.4.1. South America
          • 6.2.4.1.1. Brazil
          • 6.2.4.1.2. Argentina
          • 6.2.4.1.3. Rest of South America
        • 6.2.4.2. Asia Pacific
          • 6.2.4.2.1. China
          • 6.2.4.2.2. Japan
          • 6.2.4.2.3. India
          • 6.2.4.2.4. South Korea
          • 6.2.4.2.5. Taiwan
          • 6.2.4.2.6. Australia
          • 6.2.4.2.7. Rest of Asia-Pacific
        • 6.2.4.3. Europe
          • 6.2.4.3.1. Germany
          • 6.2.4.3.2. France
          • 6.2.4.3.3. Italy
          • 6.2.4.3.4. United Kingdom
          • 6.2.4.3.5. Netherlands
          • 6.2.4.3.6. Rest of Europe
        • 6.2.4.4. MEA
          • 6.2.4.4.1. Middle East
          • 6.2.4.4.2. Africa
        • 6.2.4.5. North America
          • 6.2.4.5.1. United States
          • 6.2.4.5.2. Canada
          • 6.2.4.5.3. Mexico
  • 7. Appendix
    • 7.1. Acronyms
  • 8. Methodology and Data Source
    • 8.1. Methodology/Research Approach
      • 8.1.1. Research Programs/Design
      • 8.1.2. Market Size Estimation
      • 8.1.3. Market Breakdown and Data Triangulation
    • 8.2. Data Source
      • 8.2.1. Secondary Sources
      • 8.2.2. Primary Sources
    • 8.3. Disclaimer
List of Tables
  • Table 1. Recombinant Proteins: by Type(USD Million)
  • Table 2. Recombinant Proteins Cytokines & Growth Factors {Interferons (IFNs), Interleukins (ILs), Others} , by Region USD Million (2019-2024)
  • Table 3. Recombinant Proteins Antibodies , by Region USD Million (2019-2024)
  • Table 4. Recombinant Proteins Immune checkpoint proteins , by Region USD Million (2019-2024)
  • Table 5. Recombinant Proteins Virus Antigens , by Region USD Million (2019-2024)
  • Table 6. Recombinant Proteins Enzymes {Kinases, Metabolic enzymes, Others} , by Region USD Million (2019-2024)
  • Table 7. Recombinant Proteins Recombinant Regulatory Protein , by Region USD Million (2019-2024)
  • Table 8. Recombinant Proteins Hormones , by Region USD Million (2019-2024)
  • Table 9. Recombinant Proteins Other , by Region USD Million (2019-2024)
  • Table 10. Recombinant Proteins: by Application(USD Million)
  • Table 11. Recombinant Proteins Drug Discovery & Development , by Region USD Million (2019-2024)
  • Table 12. Recombinant Proteins Therapeutics {Biologics, Vaccines, Cell & Gene Therapies, Others} , by Region USD Million (2019-2024)
  • Table 13. Recombinant Proteins Research , by Region USD Million (2019-2024)
  • Table 14. Recombinant Proteins Others , by Region USD Million (2019-2024)
  • Table 15. Recombinant Proteins: by End Use(USD Million)
  • Table 16. Recombinant Proteins Biopharmaceutical Companies , by Region USD Million (2019-2024)
  • Table 17. Recombinant Proteins Academic and Research Institutes , by Region USD Million (2019-2024)
  • Table 18. Recombinant Proteins Contract Research Organizations , by Region USD Million (2019-2024)
  • Table 19. Recombinant Proteins Diagnostic Laboratories , by Region USD Million (2019-2024)
  • Table 20. Recombinant Proteins Others , by Region USD Million (2019-2024)
  • Table 21. South America Recombinant Proteins, by Country USD Million (2019-2024)
  • Table 22. South America Recombinant Proteins, by Type USD Million (2019-2024)
  • Table 23. South America Recombinant Proteins, by Application USD Million (2019-2024)
  • Table 24. South America Recombinant Proteins, by End Use USD Million (2019-2024)
  • Table 25. Brazil Recombinant Proteins, by Type USD Million (2019-2024)
  • Table 26. Brazil Recombinant Proteins, by Application USD Million (2019-2024)
  • Table 27. Brazil Recombinant Proteins, by End Use USD Million (2019-2024)
  • Table 28. Argentina Recombinant Proteins, by Type USD Million (2019-2024)
  • Table 29. Argentina Recombinant Proteins, by Application USD Million (2019-2024)
  • Table 30. Argentina Recombinant Proteins, by End Use USD Million (2019-2024)
  • Table 31. Rest of South America Recombinant Proteins, by Type USD Million (2019-2024)
  • Table 32. Rest of South America Recombinant Proteins, by Application USD Million (2019-2024)
  • Table 33. Rest of South America Recombinant Proteins, by End Use USD Million (2019-2024)
  • Table 34. Asia Pacific Recombinant Proteins, by Country USD Million (2019-2024)
  • Table 35. Asia Pacific Recombinant Proteins, by Type USD Million (2019-2024)
  • Table 36. Asia Pacific Recombinant Proteins, by Application USD Million (2019-2024)
  • Table 37. Asia Pacific Recombinant Proteins, by End Use USD Million (2019-2024)
  • Table 38. China Recombinant Proteins, by Type USD Million (2019-2024)
  • Table 39. China Recombinant Proteins, by Application USD Million (2019-2024)
  • Table 40. China Recombinant Proteins, by End Use USD Million (2019-2024)
  • Table 41. Japan Recombinant Proteins, by Type USD Million (2019-2024)
  • Table 42. Japan Recombinant Proteins, by Application USD Million (2019-2024)
  • Table 43. Japan Recombinant Proteins, by End Use USD Million (2019-2024)
  • Table 44. India Recombinant Proteins, by Type USD Million (2019-2024)
  • Table 45. India Recombinant Proteins, by Application USD Million (2019-2024)
  • Table 46. India Recombinant Proteins, by End Use USD Million (2019-2024)
  • Table 47. South Korea Recombinant Proteins, by Type USD Million (2019-2024)
  • Table 48. South Korea Recombinant Proteins, by Application USD Million (2019-2024)
  • Table 49. South Korea Recombinant Proteins, by End Use USD Million (2019-2024)
  • Table 50. Taiwan Recombinant Proteins, by Type USD Million (2019-2024)
  • Table 51. Taiwan Recombinant Proteins, by Application USD Million (2019-2024)
  • Table 52. Taiwan Recombinant Proteins, by End Use USD Million (2019-2024)
  • Table 53. Australia Recombinant Proteins, by Type USD Million (2019-2024)
  • Table 54. Australia Recombinant Proteins, by Application USD Million (2019-2024)
  • Table 55. Australia Recombinant Proteins, by End Use USD Million (2019-2024)
  • Table 56. Rest of Asia-Pacific Recombinant Proteins, by Type USD Million (2019-2024)
  • Table 57. Rest of Asia-Pacific Recombinant Proteins, by Application USD Million (2019-2024)
  • Table 58. Rest of Asia-Pacific Recombinant Proteins, by End Use USD Million (2019-2024)
  • Table 59. Europe Recombinant Proteins, by Country USD Million (2019-2024)
  • Table 60. Europe Recombinant Proteins, by Type USD Million (2019-2024)
  • Table 61. Europe Recombinant Proteins, by Application USD Million (2019-2024)
  • Table 62. Europe Recombinant Proteins, by End Use USD Million (2019-2024)
  • Table 63. Germany Recombinant Proteins, by Type USD Million (2019-2024)
  • Table 64. Germany Recombinant Proteins, by Application USD Million (2019-2024)
  • Table 65. Germany Recombinant Proteins, by End Use USD Million (2019-2024)
  • Table 66. France Recombinant Proteins, by Type USD Million (2019-2024)
  • Table 67. France Recombinant Proteins, by Application USD Million (2019-2024)
  • Table 68. France Recombinant Proteins, by End Use USD Million (2019-2024)
  • Table 69. Italy Recombinant Proteins, by Type USD Million (2019-2024)
  • Table 70. Italy Recombinant Proteins, by Application USD Million (2019-2024)
  • Table 71. Italy Recombinant Proteins, by End Use USD Million (2019-2024)
  • Table 72. United Kingdom Recombinant Proteins, by Type USD Million (2019-2024)
  • Table 73. United Kingdom Recombinant Proteins, by Application USD Million (2019-2024)
  • Table 74. United Kingdom Recombinant Proteins, by End Use USD Million (2019-2024)
  • Table 75. Netherlands Recombinant Proteins, by Type USD Million (2019-2024)
  • Table 76. Netherlands Recombinant Proteins, by Application USD Million (2019-2024)
  • Table 77. Netherlands Recombinant Proteins, by End Use USD Million (2019-2024)
  • Table 78. Rest of Europe Recombinant Proteins, by Type USD Million (2019-2024)
  • Table 79. Rest of Europe Recombinant Proteins, by Application USD Million (2019-2024)
  • Table 80. Rest of Europe Recombinant Proteins, by End Use USD Million (2019-2024)
  • Table 81. MEA Recombinant Proteins, by Country USD Million (2019-2024)
  • Table 82. MEA Recombinant Proteins, by Type USD Million (2019-2024)
  • Table 83. MEA Recombinant Proteins, by Application USD Million (2019-2024)
  • Table 84. MEA Recombinant Proteins, by End Use USD Million (2019-2024)
  • Table 85. Middle East Recombinant Proteins, by Type USD Million (2019-2024)
  • Table 86. Middle East Recombinant Proteins, by Application USD Million (2019-2024)
  • Table 87. Middle East Recombinant Proteins, by End Use USD Million (2019-2024)
  • Table 88. Africa Recombinant Proteins, by Type USD Million (2019-2024)
  • Table 89. Africa Recombinant Proteins, by Application USD Million (2019-2024)
  • Table 90. Africa Recombinant Proteins, by End Use USD Million (2019-2024)
  • Table 91. North America Recombinant Proteins, by Country USD Million (2019-2024)
  • Table 92. North America Recombinant Proteins, by Type USD Million (2019-2024)
  • Table 93. North America Recombinant Proteins, by Application USD Million (2019-2024)
  • Table 94. North America Recombinant Proteins, by End Use USD Million (2019-2024)
  • Table 95. United States Recombinant Proteins, by Type USD Million (2019-2024)
  • Table 96. United States Recombinant Proteins, by Application USD Million (2019-2024)
  • Table 97. United States Recombinant Proteins, by End Use USD Million (2019-2024)
  • Table 98. Canada Recombinant Proteins, by Type USD Million (2019-2024)
  • Table 99. Canada Recombinant Proteins, by Application USD Million (2019-2024)
  • Table 100. Canada Recombinant Proteins, by End Use USD Million (2019-2024)
  • Table 101. Mexico Recombinant Proteins, by Type USD Million (2019-2024)
  • Table 102. Mexico Recombinant Proteins, by Application USD Million (2019-2024)
  • Table 103. Mexico Recombinant Proteins, by End Use USD Million (2019-2024)
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Recombinant Proteins: by Type(USD Million)
  • Table 116. Recombinant Proteins Cytokines & Growth Factors {Interferons (IFNs), Interleukins (ILs), Others} , by Region USD Million (2027-2032)
  • Table 117. Recombinant Proteins Antibodies , by Region USD Million (2027-2032)
  • Table 118. Recombinant Proteins Immune checkpoint proteins , by Region USD Million (2027-2032)
  • Table 119. Recombinant Proteins Virus Antigens , by Region USD Million (2027-2032)
  • Table 120. Recombinant Proteins Enzymes {Kinases, Metabolic enzymes, Others} , by Region USD Million (2027-2032)
  • Table 121. Recombinant Proteins Recombinant Regulatory Protein , by Region USD Million (2027-2032)
  • Table 122. Recombinant Proteins Hormones , by Region USD Million (2027-2032)
  • Table 123. Recombinant Proteins Other , by Region USD Million (2027-2032)
  • Table 124. Recombinant Proteins: by Application(USD Million)
  • Table 125. Recombinant Proteins Drug Discovery & Development , by Region USD Million (2027-2032)
  • Table 126. Recombinant Proteins Therapeutics {Biologics, Vaccines, Cell & Gene Therapies, Others} , by Region USD Million (2027-2032)
  • Table 127. Recombinant Proteins Research , by Region USD Million (2027-2032)
  • Table 128. Recombinant Proteins Others , by Region USD Million (2027-2032)
  • Table 129. Recombinant Proteins: by End Use(USD Million)
  • Table 130. Recombinant Proteins Biopharmaceutical Companies , by Region USD Million (2027-2032)
  • Table 131. Recombinant Proteins Academic and Research Institutes , by Region USD Million (2027-2032)
  • Table 132. Recombinant Proteins Contract Research Organizations , by Region USD Million (2027-2032)
  • Table 133. Recombinant Proteins Diagnostic Laboratories , by Region USD Million (2027-2032)
  • Table 134. Recombinant Proteins Others , by Region USD Million (2027-2032)
  • Table 135. South America Recombinant Proteins, by Country USD Million (2027-2032)
  • Table 136. South America Recombinant Proteins, by Type USD Million (2027-2032)
  • Table 137. South America Recombinant Proteins, by Application USD Million (2027-2032)
  • Table 138. South America Recombinant Proteins, by End Use USD Million (2027-2032)
  • Table 139. Brazil Recombinant Proteins, by Type USD Million (2027-2032)
  • Table 140. Brazil Recombinant Proteins, by Application USD Million (2027-2032)
  • Table 141. Brazil Recombinant Proteins, by End Use USD Million (2027-2032)
  • Table 142. Argentina Recombinant Proteins, by Type USD Million (2027-2032)
  • Table 143. Argentina Recombinant Proteins, by Application USD Million (2027-2032)
  • Table 144. Argentina Recombinant Proteins, by End Use USD Million (2027-2032)
  • Table 145. Rest of South America Recombinant Proteins, by Type USD Million (2027-2032)
  • Table 146. Rest of South America Recombinant Proteins, by Application USD Million (2027-2032)
  • Table 147. Rest of South America Recombinant Proteins, by End Use USD Million (2027-2032)
  • Table 148. Asia Pacific Recombinant Proteins, by Country USD Million (2027-2032)
  • Table 149. Asia Pacific Recombinant Proteins, by Type USD Million (2027-2032)
  • Table 150. Asia Pacific Recombinant Proteins, by Application USD Million (2027-2032)
  • Table 151. Asia Pacific Recombinant Proteins, by End Use USD Million (2027-2032)
  • Table 152. China Recombinant Proteins, by Type USD Million (2027-2032)
  • Table 153. China Recombinant Proteins, by Application USD Million (2027-2032)
  • Table 154. China Recombinant Proteins, by End Use USD Million (2027-2032)
  • Table 155. Japan Recombinant Proteins, by Type USD Million (2027-2032)
  • Table 156. Japan Recombinant Proteins, by Application USD Million (2027-2032)
  • Table 157. Japan Recombinant Proteins, by End Use USD Million (2027-2032)
  • Table 158. India Recombinant Proteins, by Type USD Million (2027-2032)
  • Table 159. India Recombinant Proteins, by Application USD Million (2027-2032)
  • Table 160. India Recombinant Proteins, by End Use USD Million (2027-2032)
  • Table 161. South Korea Recombinant Proteins, by Type USD Million (2027-2032)
  • Table 162. South Korea Recombinant Proteins, by Application USD Million (2027-2032)
  • Table 163. South Korea Recombinant Proteins, by End Use USD Million (2027-2032)
  • Table 164. Taiwan Recombinant Proteins, by Type USD Million (2027-2032)
  • Table 165. Taiwan Recombinant Proteins, by Application USD Million (2027-2032)
  • Table 166. Taiwan Recombinant Proteins, by End Use USD Million (2027-2032)
  • Table 167. Australia Recombinant Proteins, by Type USD Million (2027-2032)
  • Table 168. Australia Recombinant Proteins, by Application USD Million (2027-2032)
  • Table 169. Australia Recombinant Proteins, by End Use USD Million (2027-2032)
  • Table 170. Rest of Asia-Pacific Recombinant Proteins, by Type USD Million (2027-2032)
  • Table 171. Rest of Asia-Pacific Recombinant Proteins, by Application USD Million (2027-2032)
  • Table 172. Rest of Asia-Pacific Recombinant Proteins, by End Use USD Million (2027-2032)
  • Table 173. Europe Recombinant Proteins, by Country USD Million (2027-2032)
  • Table 174. Europe Recombinant Proteins, by Type USD Million (2027-2032)
  • Table 175. Europe Recombinant Proteins, by Application USD Million (2027-2032)
  • Table 176. Europe Recombinant Proteins, by End Use USD Million (2027-2032)
  • Table 177. Germany Recombinant Proteins, by Type USD Million (2027-2032)
  • Table 178. Germany Recombinant Proteins, by Application USD Million (2027-2032)
  • Table 179. Germany Recombinant Proteins, by End Use USD Million (2027-2032)
  • Table 180. France Recombinant Proteins, by Type USD Million (2027-2032)
  • Table 181. France Recombinant Proteins, by Application USD Million (2027-2032)
  • Table 182. France Recombinant Proteins, by End Use USD Million (2027-2032)
  • Table 183. Italy Recombinant Proteins, by Type USD Million (2027-2032)
  • Table 184. Italy Recombinant Proteins, by Application USD Million (2027-2032)
  • Table 185. Italy Recombinant Proteins, by End Use USD Million (2027-2032)
  • Table 186. United Kingdom Recombinant Proteins, by Type USD Million (2027-2032)
  • Table 187. United Kingdom Recombinant Proteins, by Application USD Million (2027-2032)
  • Table 188. United Kingdom Recombinant Proteins, by End Use USD Million (2027-2032)
  • Table 189. Netherlands Recombinant Proteins, by Type USD Million (2027-2032)
  • Table 190. Netherlands Recombinant Proteins, by Application USD Million (2027-2032)
  • Table 191. Netherlands Recombinant Proteins, by End Use USD Million (2027-2032)
  • Table 192. Rest of Europe Recombinant Proteins, by Type USD Million (2027-2032)
  • Table 193. Rest of Europe Recombinant Proteins, by Application USD Million (2027-2032)
  • Table 194. Rest of Europe Recombinant Proteins, by End Use USD Million (2027-2032)
  • Table 195. MEA Recombinant Proteins, by Country USD Million (2027-2032)
  • Table 196. MEA Recombinant Proteins, by Type USD Million (2027-2032)
  • Table 197. MEA Recombinant Proteins, by Application USD Million (2027-2032)
  • Table 198. MEA Recombinant Proteins, by End Use USD Million (2027-2032)
  • Table 199. Middle East Recombinant Proteins, by Type USD Million (2027-2032)
  • Table 200. Middle East Recombinant Proteins, by Application USD Million (2027-2032)
  • Table 201. Middle East Recombinant Proteins, by End Use USD Million (2027-2032)
  • Table 202. Africa Recombinant Proteins, by Type USD Million (2027-2032)
  • Table 203. Africa Recombinant Proteins, by Application USD Million (2027-2032)
  • Table 204. Africa Recombinant Proteins, by End Use USD Million (2027-2032)
  • Table 205. North America Recombinant Proteins, by Country USD Million (2027-2032)
  • Table 206. North America Recombinant Proteins, by Type USD Million (2027-2032)
  • Table 207. North America Recombinant Proteins, by Application USD Million (2027-2032)
  • Table 208. North America Recombinant Proteins, by End Use USD Million (2027-2032)
  • Table 209. United States Recombinant Proteins, by Type USD Million (2027-2032)
  • Table 210. United States Recombinant Proteins, by Application USD Million (2027-2032)
  • Table 211. United States Recombinant Proteins, by End Use USD Million (2027-2032)
  • Table 212. Canada Recombinant Proteins, by Type USD Million (2027-2032)
  • Table 213. Canada Recombinant Proteins, by Application USD Million (2027-2032)
  • Table 214. Canada Recombinant Proteins, by End Use USD Million (2027-2032)
  • Table 215. Mexico Recombinant Proteins, by Type USD Million (2027-2032)
  • Table 216. Mexico Recombinant Proteins, by Application USD Million (2027-2032)
  • Table 217. Mexico Recombinant Proteins, by End Use USD Million (2027-2032)
  • Table 218. Research Programs/Design for This Report
  • Table 219. Key Data Information from Secondary Sources
  • Table 220. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Recombinant Proteins: by Type USD Million (2019-2024)
  • Figure 5. Global Recombinant Proteins: by Application USD Million (2019-2024)
  • Figure 6. Global Recombinant Proteins: by End Use USD Million (2019-2024)
  • Figure 7. South America Recombinant Proteins Share (%), by Country
  • Figure 8. Asia Pacific Recombinant Proteins Share (%), by Country
  • Figure 9. Europe Recombinant Proteins Share (%), by Country
  • Figure 10. MEA Recombinant Proteins Share (%), by Country
  • Figure 11. North America Recombinant Proteins Share (%), by Country
  • Figure 12. Global Recombinant Proteins share by Players 2024 (%)
  • Figure 13. Global Recombinant Proteins share by Players (Top 3) 2024(%)
  • Figure 14. Global Recombinant Proteins share by Players (Top 5) 2024(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Sino Biological, Inc. (China) Revenue, Net Income and Gross profit
  • Figure 17. Sino Biological, Inc. (China) Revenue: by Geography 2024
  • Figure 18. Bio-Techne (USA) Revenue, Net Income and Gross profit
  • Figure 19. Bio-Techne (USA) Revenue: by Geography 2024
  • Figure 20. GenScript (USA) Revenue, Net Income and Gross profit
  • Figure 21. GenScript (USA) Revenue: by Geography 2024
  • Figure 22. Bio-Rad Laboratories, Inc. (USA) Revenue, Net Income and Gross profit
  • Figure 23. Bio-Rad Laboratories, Inc. (USA) Revenue: by Geography 2024
  • Figure 24. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Merck KGaA (Germany) Revenue: by Geography 2024
  • Figure 26. Thermo Fisher Scientific (USA) Revenue, Net Income and Gross profit
  • Figure 27. Thermo Fisher Scientific (USA) Revenue: by Geography 2024
  • Figure 28. Proteintech Group, Inc. (USA) Revenue, Net Income and Gross profit
  • Figure 29. Proteintech Group, Inc. (USA) Revenue: by Geography 2024
  • Figure 30. Enzo Life Sciences, Inc. (USA) Revenue, Net Income and Gross profit
  • Figure 31. Enzo Life Sciences, Inc. (USA) Revenue: by Geography 2024
  • Figure 32. Abnova Corporation (Taiwan) Revenue, Net Income and Gross profit
  • Figure 33. Abnova Corporation (Taiwan) Revenue: by Geography 2024
  • Figure 34. RayBiotech Life Inc. (USA) Revenue, Net Income and Gross profit
  • Figure 35. RayBiotech Life Inc. (USA) Revenue: by Geography 2024
  • Figure 36. STEMCELL Technologies Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 37. STEMCELL Technologies Inc. (Canada) Revenue: by Geography 2024
  • Figure 38. Global Recombinant Proteins: by Type USD Million (2027-2032)
  • Figure 39. Global Recombinant Proteins: by Application USD Million (2027-2032)
  • Figure 40. Global Recombinant Proteins: by End Use USD Million (2027-2032)
  • Figure 41. South America Recombinant Proteins Share (%), by Country
  • Figure 42. Asia Pacific Recombinant Proteins Share (%), by Country
  • Figure 43. Europe Recombinant Proteins Share (%), by Country
  • Figure 44. MEA Recombinant Proteins Share (%), by Country
  • Figure 45. North America Recombinant Proteins Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Sino Biological, Inc. (China)
  • Bio-Techne (USA)
  • GenScript (USA)
  • Bio-Rad Laboratories, Inc. (USA)
  • Merck KGaA (Germany)
  • Thermo Fisher Scientific (USA)
  • Proteintech Group, Inc. (USA)
  • Enzo Life Sciences, Inc. (USA)
  • Abnova Corporation (Taiwan)
  • RayBiotech Life Inc. (USA)
  • STEMCELL Technologies Inc. (Canada)
Select User Access Type

Key Highlights of Report


Feb 2025 228 Pages 64 Tables Base Year: 2024 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Recombinant Proteins Quantitative research analysis
Global Recombinant Proteins Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Sino Biological, Inc. (China), Bio-Techne (USA), GenScript (USA), Bio-Rad Laboratories, Inc. (USA), Merck KGaA (Germany), Thermo Fisher Scientific (USA), Proteintech Group, Inc. (USA), Enzo Life Sciences, Inc. (USA), Abnova Corporation (Taiwan), RayBiotech Life Inc. (USA) and STEMCELL Technologies Inc. (Canada) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"" is seen as one of major influencing trends for Recombinant Proteins Market during projected period 2024-2032.
The Recombinant Proteins market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Recombinant Proteins Report?

Have a Query? Click Here

Other Related Reports

Cell Separation Technologies Comprehensive Study by Type (Gradient Centrifugation, Surface Markers Separation (Fluorescence-activated cell sorting (FACS), Magnetic-Activated Cell Sorting (MACS), Filt...
$ 3750
Confocal Raman Microscopes Comprehensive Study by Type (Desktop, Portable), Application (Pharmaceutics, R&D in Academia, Industrial Sector, Others) Players and Region - Global Market Outlook to 2027
$ 3500
Cell Signaling Comprehensive Study by Type (Endocrine Signaling, Paracrine Signaling, Autocrine Signaling, Juxtacrine Signaling, Other Signaling Types), Application (Research Applications , Medical A...
$ 3500
Micro Bioreactors Comprehensive Study by Type (24 Parallel Bioreactors, 48 Parallel Bioreactors, Others), Application (Sewage Treatment, Biochemical Engineering, Food Industry, Others), End User (Pha...
$ 3450
Cell Sorter Comprehensive Study by Type (Cell Sorters, Cell Sorting Reagents & Consumables, Cell Sorting Services), Application (Research Application, Immunology & Cancer Research, Stem Cell Research...
$ 3750
Pharmaceutical Plant Extracts Comprehensive Study by Type (Non-standardized Extracts, Standardized Extracts), Application (Ayurveda, Traditional Chinese Medicine, Western Herbalism, Homeopathy, Other...
$ 3650